IRIS
Narcisi, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.570
NA - Nord America 3.510
SA - Sud America 1.085
EU - Europa 756
Continente sconosciuto - Info sul continente non disponibili 185
AF - Africa 115
OC - Oceania 3
AN - Antartide 1
Totale 9.225
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.346
SG - Singapore 2.030
BR - Brasile 855
CN - Cina 605
VN - Vietnam 546
IT - Italia 232
HK - Hong Kong 100
AR - Argentina 99
CA - Canada 75
FI - Finlandia 73
IE - Irlanda 66
IN - India 60
FR - Francia 56
GB - Regno Unito 56
DE - Germania 51
MX - Messico 48
EC - Ecuador 46
ID - Indonesia 35
BD - Bangladesh 33
RU - Federazione Russa 33
NL - Olanda 29
ZA - Sudafrica 28
NG - Nigeria 27
CO - Colombia 26
SE - Svezia 24
PL - Polonia 22
BE - Belgio 21
UA - Ucraina 21
ES - Italia 20
IQ - Iraq 20
PK - Pakistan 20
JP - Giappone 19
TR - Turchia 18
VE - Venezuela 15
MA - Marocco 14
PY - Paraguay 14
MY - Malesia 11
TN - Tunisia 11
CL - Cile 9
HN - Honduras 9
PE - Perù 9
DZ - Algeria 8
KE - Kenya 8
NP - Nepal 7
EG - Egitto 6
PH - Filippine 6
UZ - Uzbekistan 6
XK - ???statistics.table.value.countryCode.XK??? 6
AT - Austria 5
CZ - Repubblica Ceca 5
DO - Repubblica Dominicana 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LT - Lituania 5
SA - Arabia Saudita 5
TH - Thailandia 5
UY - Uruguay 5
AL - Albania 4
BO - Bolivia 4
ET - Etiopia 4
IL - Israele 4
JM - Giamaica 4
LV - Lettonia 4
OM - Oman 4
PS - Palestinian Territory 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
AZ - Azerbaigian 3
BH - Bahrain 3
CH - Svizzera 3
CR - Costa Rica 3
EE - Estonia 3
GE - Georgia 3
HU - Ungheria 3
NI - Nicaragua 3
PA - Panama 3
RO - Romania 3
SR - Suriname 3
BG - Bulgaria 2
BY - Bielorussia 2
GR - Grecia 2
GT - Guatemala 2
KW - Kuwait 2
LB - Libano 2
LY - Libia 2
MT - Malta 2
PR - Porto Rico 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BZ - Belize 1
DK - Danimarca 1
GA - Gabon 1
GN - Guinea 1
Totale 9.033
Salva come PNG Salva come JPEG
Città #
Singapore 666
Ashburn 407
San Jose 346
Chandler 245
Shanghai 210
Council Bluffs 194
Ho Chi Minh City 190
Dallas 189
Beijing 177
The Dalles 167
Hanoi 100
New York 99
Hong Kong 98
Los Angeles 95
Santa Clara 93
Boardman 89
Milan 88
Wilmington 87
Helsinki 73
São Paulo 69
Dublin 65
San Mateo 45
Princeton 38
Ann Arbor 35
Lawrence 34
Haiphong 31
Buffalo 30
Phoenix 30
Brooklyn 28
Benin City 27
Chicago 26
Da Nang 26
Paris 26
Rio de Janeiro 26
Rome 22
Brussels 21
Mexico City 21
Guayaquil 18
Orem 18
Belo Horizonte 17
Tokyo 17
Hải Dương 16
London 16
Montreal 16
Seattle 16
Warsaw 16
Amsterdam 15
Can Tho 15
Johannesburg 15
Toronto 15
Atlanta 14
Leawood 14
Charlotte 13
Assago 12
Buenos Aires 12
Chennai 12
Curitiba 12
Fairfield 12
Quito 12
Salvador 12
Boston 11
Figino 11
Frankfurt am Main 11
Brasília 10
Ninh Bình 10
Houston 9
Richmond 9
San Francisco 9
Dronten 8
Falkenstein 8
Jakarta 8
Lima 8
Mumbai 8
Nairobi 8
Poplar 8
Porto Alegre 8
Sorocaba 8
São Bernardo do Campo 8
Thái Bình 8
Bauru 7
Campinas 7
Dhaka 7
Goiânia 7
Munich 7
Philadelphia 7
Phủ Lý 7
Recife 7
Teresina 7
Tây Ninh 7
Uberlândia 7
Woodbridge 7
Anápolis 6
Baghdad 6
Biên Hòa 6
Bắc Giang 6
Cape Town 6
Caracas 6
Ha Long 6
Istanbul 6
Lewistown 6
Totale 4.854
Salva come PNG Salva come JPEG
Nome #
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 204
Brodalumab: a new way to inhibit IL-17 in psoriasis 127
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 120
Chronic Hand Eczema (CHE): A Narrative Review 116
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) 110
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 109
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis) 103
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 100
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 97
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 95
Programmed cell death in the skin 94
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 93
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 88
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 88
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 86
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 86
25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies 85
Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study) 85
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 83
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 82
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 79
Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders 79
Measuring psoriatic disease in clinical practice. An expert opinion position paper 79
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 77
Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? 76
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab 74
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks 72
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) 72
Noninvasive Assessment and Management of Folliculitis Decalvans by Trichoscopy and Reflectance Confocal Microscopy 72
noveaux horizon therapeutiques pour le prurit dermatologique au delà de la dermatite atopique: role de i-modulia 71
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab 69
Long-term safety of etanercept in psoriasis: Retrospective study focused on infections 69
Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report 69
Diagnostic imaging: Listening in to skin disease 68
Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital 67
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study 65
Palmar nodules in a young woman with ulcerative colitis and enteropathic arthritis 65
TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. 65
Potential Role of Leptin in JAK2 Inhibitor-Associated Weight Gain: A Monocentric Retrospective Study 64
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 64
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study 63
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study 61
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) 61
An 18-year follow-up of a case of D-penicillamine-induced Elastosis perforans serpiginosa 61
Suicide risk and psychiatric comorbidity in patients with psoriasis 60
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis) 59
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis) 59
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 56
Daily Patient's Relief From Pruritus and Sleep Disturbance Over One-Month Treatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Multicenter Prospective Study 56
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study 56
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis) 55
Update on the Management of Pediatric Psoriasis: An Italian Consensus 54
Bullous vasculitis associated with Streptococcus pyogenes sepsis 54
Urticarial rash in autoinflammatory syndromes 54
What Can IBD Specialists Learn from IL-23 Trials in Dermatology? 54
Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction 53
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study 53
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review 53
Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab 52
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study 52
Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis 51
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study 51
Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) 51
Fingertip dermatitis: a spy for psoriasis 51
An unusual case of annular bollous eruption of the inguinal folds 50
Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy 50
A case of lichen amyloidosus treated with acitretin 50
Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It? 50
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis 49
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis 49
Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel 48
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study 48
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment 48
Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report 48
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 48
Disseminated Superficial Porokeratosis with Dermal Amyloid Deposits 47
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis) 47
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) 47
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study 47
A Case of Ketron-Goodman Disease 47
A case of cutaneous large B-cell lymphoma of the legs appearing as chronic venous ulceration 46
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers 46
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience 45
An updated safety review of Hidradenitis Suppurativa treatment options 45
Allergy to nickel: first results on patients administered with an oral hyposensitization therapy 45
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience 44
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study 44
Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients 44
Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study 44
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma 44
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus 43
A case of periocular contact dermatitis caused by cypress allergy 43
Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals 43
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis) 43
Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience 43
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination 42
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study 42
Cutaneous hypersensitivity to gluten 42
Atypical facial pustular folliculitis by Klebsiella pneumoniae: a case report 42
An extrafacial amelanotic lentigo maligna of the leg: a case report 41
Totale 6.441
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.854
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.854
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022152 0 0 5 31 1 0 9 21 13 17 46 9
2022/2023609 82 48 46 87 59 45 1 48 99 47 41 6
2023/2024623 25 49 126 27 15 60 60 66 16 20 64 95
2024/20251.333 15 22 19 18 8 111 94 68 170 242 215 351
2025/20265.532 689 407 537 854 297 228 1.079 319 305 301 214 302
2026/2027816 470 346 0 0 0 0 0 0 0 0 0 0
Totale 9.225